Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report

RATIONALE: Mounting evidences reveal that mutation of epidermal growth factor receptor (EGFR) may induce the resistance of tyrosine kinase inhibitors (TKIs). TKI-resistant lung cancer cells are sensitive to inhibition of the EGFR pathway. This case report aimed to characterize the therapeutic benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ka, Guo, Chao, Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504272/
https://www.ncbi.nlm.nih.gov/pubmed/31045832
http://dx.doi.org/10.1097/MD.0000000000015489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504272/
https://www.ncbi.nlm.nih.gov/pubmed/31045832
http://dx.doi.org/10.1097/MD.0000000000015489

Ejemplares similares